170 likes | 411 Views
PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors. Scott Kopetz 1 , Jayesh Desai 2 , Emily Chan 3 , J Randolph Hecht 4 , Peter J O’Dwyer 5 , Richard J Lee 6 , Keith B Nolop 7 , Suman Bhattacharya 8 , Leonard Saltz 9
E N D
PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors Scott Kopetz1, Jayesh Desai2, Emily Chan3, J Randolph Hecht4 , Peter J O’Dwyer5, Richard J Lee6, Keith B Nolop7, Suman Bhattacharya8, Leonard Saltz9 1 The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2 Royal Melbourne Hospital, Parkville, Australia; 3 Vanderbilt-Ingram Cancer Center, Nashville, TN; 4 David Geffen School of Medicine at UCLA, Los Angeles, CA; 5 Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA; 6 Roche, Nutley, NJ; 7 Plexxikon, Berkeley, CA; 8 Genentech, Inc., South San Francisco, CA; 9 Memorial Sloan-Kettering Cancer Center, New York, NY